Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 713768 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
Hard CopyAdd to Basket
ElectronicAdd to Basket



Sonus Pharmaceuticals Inc: Premium Company Profile
Datamonitor, Jan 2008, Pages: 41


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

Sonus Pharmaceuticalss main focus is to discover, develop and commercialize products for the treatment of diseases in the therapeutic area of oncology. The company seeks to build a franchise of oncology products through its own internal efforts.

Scope

- Contains corporate strategy, value chain presence and SWOT Analysis

- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors

- Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights of this title

Sonus Pharmaceuticals is focused on the discovery, development and commercialization of pharmaceutical products for oncology indications. The company has only one program in its pipeline, namely, TOCOSOL Camptothecin, for the treatment of solid tumors.

Sonus derives its revenues from collaboration and licensing agreements. These revenues are related to the collaboration agreement with Bayer Schering, under which Bayer Schering was granted worldwide exclusive license to market and promote TOCOSOL Paclitaxel and was responsible for clinical development and regulatory activities outside of the US.

Sonus aims to apply its focus on advancing its second oncology product candidate, TOCOSOL Camptothecin, which was moved into a Phase I clinical trial in September 2006. In addition, it intends to identify and acquire products/technologies that are complementary to its focus in oncology in order to broaden the business and market opportunities.

Key reasons to purchase this title

- Access all the important information and analysis on the company in a single report

- Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain

- Gain access to companys adjusted five year financial data along with key ratios and market capitalization




Customers who bought this item also bought

Sonus Networks (Company Advisor)

Sonus Pharmaceuticals Inc.-Therapeutic Competitors

Sonus Networks - Sonus Softswitch (Product Advisor)

Sonus Networks - Insignus (Product Advisor)

Sonus Networks, Inc.

Sonus Pharmaceuticals Inc.-Financial Company Report

Sonus Networks - GSX9000 Open Services Switch (Product Advisor)

Sonus Pharmaceuticals Inc.-Detailed Product Pipeline

Sonus Networks - Company Advisor

Sonus Pharmaceuticals Inc.-Deals & Alliances Report

SONUS NETWORKS - World'Vest Base Business Risk

SONUS NETWORKS - World'Vest Base Credit Risk



Top of page


   All rights reserved. � Copyright 2010 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds